Zealand Pharma: Positive results from pivotal Phase III clinical trials with iGlarLixi
Monday, June 13, 2016
Zealand Pharma A/S Positive results from pivotal Phase III clinical trials with iGlarLixi.
Type 2 diabetes patients treated with iGlarLixi (formerly LixiLan) had significantly greater reductions in blood glucose (HbA1c) versus treatment with either lixisenatide or Lantus.
Treatment with iGlarLixi also resulted in body weight reduction versus Lantus.
Positive Phase III results support Zealand's potential for revenue growth from milestone payments and royalties on iGlarLixi, if approved.
Regulatory decisions by U.S. FDA and by EMA in Europe are expected in August and in Q1 2017, respectively.
Source : reuters.com
